Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Genomic Studies Reveal Links Between Prostate Cancer and Cardiovascular Disease

By BiotechDaily International staff writers
Posted on 13 May 2014
Image: Micrograph of normal prostatic glands and those with prostate adenocarcinoma (upper right portion of image) (Photo courtesy of Wikimedia Commons).
Image: Micrograph of normal prostatic glands and those with prostate adenocarcinoma (upper right portion of image) (Photo courtesy of Wikimedia Commons).
A large-scale statistical evaluation of genomic studies linked to either prostate cancer (PCA) or cardiovascular disease (CVD) risk identified 17 genetic loci that link prostate cancer to risk of developing CVD.

Investigators at Oslo University (Norway) and their colleagues at the University of California, San Diego (USA) applied a genetic epidemiology method based on conjunction false discovery rate (FDR) that combined summary statistics from different genome-wide association studies (GWAS), and allowed identification of genetic overlap between two phenotypes. FDR is a statistical method used in multiple hypotheses testing to correct for multiple comparisons. In a list of findings, FDR procedures are designed to control the expected proportion of incorrectly rejected null hypotheses.

The investigators evaluated summary statistics from large, multicenter GWA studies of PCA (n = 50,000) and CVD risk factors (n = 200,000). CVD risk factors included triglycerides (TG), low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, systolic blood pressure, body mass index, waist-hip ratio, and type II diabetes.

Results published in the April 30, 2014, online edition of the International Journal of Epidemiology revealed that the strongest association between PCA and CVD risk was conditional on LDL and TG. In contrast, the investigators found only weak enrichment conditional on HDL or conditional on the other traits investigated. Conjunction FDR identified altogether 17 loci; 10 loci were associated with PCA and LDL, three loci were associated with PCA and TG and additionally four loci were associated with PCA, LDL, and TG jointly.

"It is fair to say that risk relationships of various sorts have been proposed between prostate cancer and cardiovascular disease, although not comorbidity per se," said contributing author Dr. Ian G. Mills, researcher in the prostate cancer group at the University of Oslo. "There is a lack of consistency across cohorts, however, in size and direction of effects, depending on cardiovascular risk factor considered. The significant risk association with LDL cholesterol and triglycerides versus the other traits at a genetic level was novel and unexpected."

Related Links:

Oslo University
University of California, San Diego



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.